Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 16, 2024; 12(11): 1918-1928
Published online Apr 16, 2024. doi: 10.12998/wjcc.v12.i11.1918
Chaiqin Chengqi Decoction as an adjuvant treatment for mild/moderately severe hypertriglyceridemic acute pancreatitis: A retrospective study
Hai-Fu Zhang, Ze-Xuan Su, Yong-Hang Feng, Shuo-Jun Li, Bi-Yun Xie
Hai-Fu Zhang, Ze-Xuan Su, Yong-Hang Feng, Shuo-Jun Li, Bi-Yun Xie, Department of Internal Medicine, The First People's Hospital of Fuyang, Hangzhou 311400, Zhejiang Province, China
Co-first authors: Hai-Fu Zhang and Ze-Xuan Su.
Author contributions: Zhang HF and Su ZX contributed equally to this work as co-first authors; Zhang HF and Su ZX carried out data curation; Zhang HF and Xie BY were responsible for designing the research study and writing the paper; Feng YH and Li SJ conducted data analysis and completed the visualization process.
Supported by The Hangzhou Science and Technology Bureau, No. B20230285.
Institutional review board statement: This study is a retrospective study, and the use of patient clinical data has passed ethical review, ethical review No. 2022-lw (031).
Informed consent statement: The study received approval from the institutional review board of The First People's Hospital of Fuyang, and the requirement for informed consent was waived.
Conflict-of-interest statement: The authors declare that there are no competing interests associated with the manuscript.
Data sharing statement: The data that support the findings of this study are not publicly available due to their containing information that could compromise the privacy of research participants but are available from the corresponding author Bi-Yun Xie upon reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bi-Yun Xie, MD, Doctor, Department of Internal Medicine, The First People's Hospital of Fuyang, No. 429 Beihuan Road, Fuchun Street, Fuyang District, Hangzhou 311400, Zhejiang Province, China. angisxie@163.com
Received: November 26, 2023
Peer-review started: November 26, 2023
First decision: January 24, 2024
Revised: February 6, 2024
Accepted: March 20, 2024
Article in press: March 20, 2024
Published online: April 16, 2024
Abstract
BACKGROUND

Hypertriglyceridemia is the third leading cause of acute pancreatitis (AP), and its incidence is increasing. Due to its relatively insidious etiology, it is easy to be ignored in the early stages. In China, Chaiqin Chengqi Decoction (CQCQD) has long been employed for treating AP.

AIM

To evaluate the effectiveness of CQCQD in patients diagnosed with mild/ moderately severe hypertriglyceridemic AP (HTG-AP).

METHODS

In this study, the clinical data of 39 patients with HTG-AP admitted from January 2019 to November 2022 were collected. The changes of blood lipids, gastrointestinal symptoms, and abdominal pain before and after treatment were analyzed and compared between the two groups.

RESULTS

Twenty patients were treated with the conventional HTG-AP regimen, and 19 patients were additionally treated with CQCQD. After receiving treatment, the triglycerides (TG) level of the CQCQD group was lower than that of the CQCQD group (3.14 ± 0.25 mmol/L vs 4.96 ± 0.47 mmol/L, P < 0.01). After 3 d of treatment, the patients in the CQCQD group had more bowel movements than the control group (2.51 ± 0.25 times vs 1.00 ± 0.17 times, P = 0.01). The gastrointestinal function of most patients returned to normal, and the acute gastrointestinal injury score was significantly lower than that of the control group (0.11 ± 0.07 vs 0.42 ± 0.11, P < 0.01).

CONCLUSION

In patients with HTG-AP, CQCQD can significantly reduce the TG level, shorten the recovery time of defecation, significantly improve the gastrointestinal function.

Keywords: Hypertriglyceridemic acute pancreatitis, Chinese medicine, Chaiqin Chengqi Decoction, Serum lipid, Triglycerides

Core Tip: Applying Chaiqin Chengqi Decoction (CQCQD) for treating acute pancreatitis (AP) has a long-standing history in China. To validate the efficacy of CQCQD in treating hypertriglyceridemic AP (HTG-AP), we conducted a retrospective analysis of patients with HTG-AP treated at our hospital. We compared and analyzed changes in blood lipid levels, gastrointestinal symptoms, and abdominal pain before and after treatment. Following treatment, the CQCQD group exhibited significantly lower triglyceride levels compared to the control group (3.14 ± 0.25 mmol/L vs 4.96 ± 0.47 mmol/L, P < 0.01). Additionally, shortened defecation recovery time and a notable improvement in gastrointestinal function were observed.